Our study highlights the potential of a novel Septin9 methylation assay designed for CRC screening, specifically focusing on the simultaneous detection of two different CpG islands of the Septin9 gene in plasma samples. This evidence concerns the gene SEPTIN9 and colorectal carcinoma.